AP source: Pfizer seeking OK for 4th COVID dose for seniors
Drugmaker Pfizer is expected to request authorization this week for an additional COVID-19 booster dose for seniors
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Drugmaker Pfizer is expected to request authorization this week for an additional COVID-19 booster dose for seniors, according to a person familiar with the matter.
It would add a fourth dose to the regimen, which currently consists of a primary series of two shots, followed months later by a booster dose, in an effort to provide maximum protection to the over-65 population that has been hit hardest by the pandemic.
The Food and Drug Administration and the Centers for Disease Control must approve the request. The person who spoke about the upcoming Pfizer authorization request spoke on condition of anonymity because the person wasn’t authorized to speak on the record.
“We’re continuing to collect and assess all available data and we’re in continuous, open dialogue with regulators and health authorities to help inform a COVID-19 vaccine strategy as the virus evolves,” said Pfizer spokeswoman Jerica Pitts.
Speaking to CBS' “Face the Nation” on Sunday, Pfizer CEO Albert Bourla said, “Right now, the way that we have seen, it is necessary, a fourth booster right now. The protection that you are getting from the third, it is good enough, actually quite good for hospitalizations and deaths. It’s not that good against infections, but doesn’t last very long. But we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer."